Ralph Ermoian

Dr. Ralph Ermoian

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2019 in Blood
Verified
Journal Article
Open access
PDF file
KBKevin Scott Baker
Kevin Scott Baker
WLWendy M. Leisenring
Wendy M. Leisenring
PGPamela J. Goodman
Pamela J. Goodman
RERalph Ermoian
Ralph Ermoian
MFMary E. Flowers
Mary E. Flowers
HDH. Joachim Deeg
H. Joachim Deeg
We examined the impact of total body irradiation (TBI) dose and fractionation on risk of subsequent malignant neoplasms (SMNs) in the era of reduced-intensity and nonmyeloablative conditioning regimens for hematopoietic cell transplantation (HCT). Among 4905 1-year survivors of allogeneic HCT for hematologic malignancies (N = 4500) or nonmalignant disorders (N = 405) who received transplants between 1969 and 2014, we identified 581 SMNs (excluding squamous and basal cell of skin) in 499 individuals. With a median length of follow-up of 12.5 years, the cumulative incidence of SMNs by 30 years after HCT was 22.0%. Compared with age-, sex-, and calendar year–matched Surveillance, Epidemiology, and End Results (SEER) population rates, the standardized incidence ratio (SIR) of SMNs was increased 2.8-fold. The highest SIRs were for SMNs of bones (SIR, 28.8), oral cavity (SIR, 13.8), skin (SIR, 7.3), central nervous system (SIR, 6.0), and endocrine organs (SIR, 4.9). The highest excess absolute risks (EARs) were seen with breast cancer (EAR, 2.2) and cancers of the oral cavity (EAR, 1.5) and skin (EAR, 1.5) per 1000 person-years. The highest incidence of SMNs was in survivors exposed to unfractionated (600-1000 cGy) or high-dose fractionated (1440-1750 cGy) TBI. For patients receiving low-dose TBI, the incidence was comparable to myeloablative chemotherapy alone, although still twofold higher than in the general population. These data demonstrate a strong effect of TBI dose, dose fractionation, and risk of SMNs after HCT. The cumulative incidence of SMNs increases with follow-up time; thus, HCT survivors require lifetime monitoring for early detection and effective therapy of SMNs.

1 November 2017 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
ARAvani D. Rao
Avani D. Rao
ARArif S. Rashid
Arif S. Rashid
QCQinyu Chen
Qinyu Chen
RVRosangela C. Villar
Rosangela C. Villar
DKDaria Kobyzeva
Daria Kobyzeva
STStephanie A. Terezakis
Stephanie A. Terezakis

26 May 2017 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
RERalph Ermoian
Ralph Ermoian
JBJohn Breneman
John Breneman
DWDavid O. Walterhouse
David O. Walterhouse
YCYueh‐Yun Chi
Yueh‐Yun Chi
JMJane Meza
Jane Meza
SWSuzanne L. Wolden
Suzanne L. Wolden

1 March 2020 in British Journal of Radiology
Verified
Journal Article
Closed access
MLMiranda P. Lawell
Miranda P. Lawell
DIDaniel J Indelicato
Daniel J Indelicato
APArnold C. Paulino
Arnold C. Paulino
WHWilliam Hartsell
William Hartsell
NLNadia Laack
Nadia Laack
TYTorunn I. Yock
Torunn I. Yock
Objective: The Pediatric Proton/Photon Consortium Registry (PPCR) is a comprehensive data registry composed of pediatric patients treated with radiation. It was established to expedite outcomes-based research. The attributes which allow the PPCR to be a successful collaboration are reviewed. Methods and materials: Current eligibility criteria are radiotherapy patients < 22 years treated at one of the 15 US participating institutions. Detailed health and treatment data are collected about the disease presentation and treatment exposures, and annually thereafter, in REDCap (Research Electronic Data Capture). DICOM (Digital Imaging and Communications in Medicine) imaging and radiation plans are collected through MIM/MIMcloud. An optional patient-reported quality-of-life (PedsQL) study is administered at 10 sites. Results: Accrual started October 2012 with 2,775 participants enrolled as of 25 July 2019. Most patients, 62.0%, were treated for central nervous system (CNS) tumors, the most common of which are medulloblastoma (n = 349), ependymoma (n = 309), and glial/astrocytoma tumors (n = 279). The most common non-CNS diagnoses are rhabdomyosarcoma (n = 284), Ewing’s sarcoma (n = 153), and neuroblastoma (n = 130). While the majority of participants are US residents, 18.7% come from 36 other countries. Over 685 patients participate in the PedsQL study. Conclusions: The PPCR is a valuable research platform capable of answering countless research questions that will ultimately improve patient care. Centers outside of the USA are invited to participate directly or may engage with the PPCR to align data collection strategies to facilitate large-scale international research. Advances in knowledge: For investigators looking to carry out research in a large pediatric oncology cohort or interested in registry work, this paper provides an updated overview of the PPCR.

11 July 2017 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
ARAvani Dholakia Rao
Avani Dholakia Rao
QCQinyu Chen
Qinyu Chen
RERalph Ermoian
Ralph Ermoian
SASara R. Alcorn
Sara R. Alcorn
MFMaria Luisa S. Figueiredo
Maria Luisa S. Figueiredo
STStephanie A. Terezakis
Stephanie A. Terezakis

1 May 2018 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
HDH. Joachim Deeg
H. Joachim Deeg
ESEmily A. Stevens
Emily A. Stevens
RSRachel B. Salit
Rachel B. Salit
RERalph Ermoian
Ralph Ermoian
MFMin Fang
Min Fang
BSBarry E. Storer
Barry E. Storer
In this prospective, randomized, phase II "pick the winner" trial we assessed the efficacy of transplant conditioning with treosulfan/fludarabine ± 2 Gy total body irradiation (TBI) in reducing post-transplant relapse in 100 patients, aged 2 to 70 years (median, 57), with myelodysplastic syndrome (MDS)/chronic myelomonocytic leukemia (n = 51) or acute myeloid leukemia (AML; n = 49). Patients received i.v. treosulfan, 14 g/m2/day on days -6 to -4 and i.v. fludarabine, 30 mg/m2/day on days -6 to -2, alone or combined with 2 Gy TBI (day 0). Donors were related (n = 43) or unrelated (n = 57). When a planned interim analysis showed superior progression-free survival in the TBI arm (P = .04), all subsequent patients received TBI. With a follow-up of 12 to 40 months (median, 20), the 1-year overall survival was 80% for the TBI arm and 69% for the non-TBI arm. The 1-year cumulative incidence of relapse was 22% and 34%, respectively (P = .06). Among patients with low-risk disease the 1-year relapse incidence was 15% and 31% (P = .20) and for patients with high-risk disease, 26% and 36% (P = .18), respectively. Among MDS patients the 1-year relapse incidence was 27% versus 33% (P = .49) and among AML patients 16% versus 35% (P = .05), respectively. The largest difference was among patients with unfavorable cytogenetics, with 1-year relapse incidences of 31% and 63% (P = .18), respectively. Nonrelapse mortality in this high-risk patient population was 9% at 6 months and did not differ between arms. Thus, treosulfan/fludarabine/low-dose TBI provided effective conditioning for allogeneic hematopoietic cell transplantation in high-risk patients up to 70 years of age. The addition of TBI had a more profound effect in patients with AML than in those with MDS. High-risk disease features were associated with a lower overall success rate. Further studies are warranted.